UNLABELLED: Osteoporosis after spinal cord injury is common. Reductions in bone density are rapid and fracture rates are higher after injury. Early treatment with 4 mg zoledronic acid significantly reduced bone loss at the hip compared to untreated individuals in the first year. Treatment appeared safe and well tolerated. INTRODUCTION:Bone mineral density (BMD) is lost rapidly following spinal cord injury (SCI), predominantly in the lower limbs. Bone turnover markers suggest an early increase in resorption. METHODS: A randomised, open-label study of 14 patients with acute SCI randomised toreceive 4 mg IV zoledronic acid or standard treatment. BMD was measured by dual-X-ray absorptiometry at the lumbar spine and hip (femoral neck, total and trochanter) at baseline, 3, 6 and 12 months. Bone turnover markers (serum C-terminal telopeptide and Procollagen I N-terminal peptide and urinary N-terminal telopeptide/Cr ratio) were also measured. RESULTS: After 12 months, there was a significant difference in BMD between the groups at the total hip (12.4%, p = 0.005), trochanter (13.4%, p = 0.028) and lumbar spine (2.7%, p = 0.033). However, the difference between groups at the femoral neck was not significant (4.8%, p = 0.741). In the treated group, bone resorption was reduced and remained reduced up to 12 months. Other than flu-like symptoms immediately after the infusion, no adverse events were observed. CONCLUSION:IV zoledronic acid is an effective and well-tolerated treatment to prevent bone mineral density loss at the total hip and trochanter for up to 12 months following SCI.
RCT Entities:
UNLABELLED: Osteoporosis after spinal cord injury is common. Reductions in bone density are rapid and fracture rates are higher after injury. Early treatment with 4 mg zoledronic acid significantly reduced bone loss at the hip compared to untreated individuals in the first year. Treatment appeared safe and well tolerated. INTRODUCTION: Bone mineral density (BMD) is lost rapidly following spinal cord injury (SCI), predominantly in the lower limbs. Bone turnover markers suggest an early increase in resorption. METHODS: A randomised, open-label study of 14 patients with acute SCI randomised to receive 4 mg IV zoledronic acid or standard treatment. BMD was measured by dual-X-ray absorptiometry at the lumbar spine and hip (femoral neck, total and trochanter) at baseline, 3, 6 and 12 months. Bone turnover markers (serum C-terminal telopeptide and Procollagen I N-terminal peptide and urinary N-terminal telopeptide/Cr ratio) were also measured. RESULTS: After 12 months, there was a significant difference in BMD between the groups at the total hip (12.4%, p = 0.005), trochanter (13.4%, p = 0.028) and lumbar spine (2.7%, p = 0.033). However, the difference between groups at the femoral neck was not significant (4.8%, p = 0.741). In the treated group, bone resorption was reduced and remained reduced up to 12 months. Other than flu-like symptoms immediately after the infusion, no adverse events were observed. CONCLUSION: IV zoledronic acid is an effective and well-tolerated treatment to prevent bone mineral density loss at the total hip and trochanter for up to 12 months following SCI.
Authors: D Roberts; W Lee; R C Cuneo; J Wittmann; G Ward; R Flatman; B McWhinney; P E Hickman Journal: J Clin Endocrinol Metab Date: 1998-02 Impact factor: 5.958
Authors: David Hosking; Kenneth Lyles; Jacques P Brown; William D Fraser; Paul Miller; Manuel Diaz Curiel; Jean-Pierre Devogelaer; Michael Hooper; Guoqin Su; Ken Zelenakas; Judy Pak; Taiwo Fashola; Youssef Saidi; Erik Fink Eriksen; Ian R Reid Journal: J Bone Miner Res Date: 2007-01 Impact factor: 6.741
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: William A Bauman; Christopher M Cirnigliaro; Michael F La Fountaine; LeighAnn Martinez; Steven C Kirshblum; Ann M Spungen Journal: J Bone Miner Metab Date: 2014-08-27 Impact factor: 2.626
Authors: L Gifre; J Vidal; J L Carrasco; A Muxi; E Portell; A Monegal; N Guañabens; P Peris Journal: Osteoporos Int Date: 2015-05-05 Impact factor: 4.507
Authors: C M Cirnigliaro; M J Myslinski; M F La Fountaine; S C Kirshblum; G F Forrest; W A Bauman Journal: Osteoporos Int Date: 2016-12-05 Impact factor: 4.507
Authors: L Abderhalden; F M Weaver; M Bethel; H Demirtas; S Burns; J Svircev; H Hoenig; K Lyles; S Miskevics; L D Carbone Journal: Osteoporos Int Date: 2016-12-06 Impact factor: 4.507
Authors: M Bethel; F M Weaver; L Bailey; S Miskevics; J N Svircev; S P Burns; H Hoenig; K Lyles; L D Carbone Journal: Osteoporos Int Date: 2016-05-26 Impact factor: 4.507
Authors: L Gifre; L Humbert; A Muxi; L Del Rio; J Vidal; E Portell; A Monegal; N Guañabens; P Peris Journal: Osteoporos Int Date: 2017-10-17 Impact factor: 4.507